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Available online 8 April 2008A SARS vaccine based on a live-attenuated vesicular stomatitis virus (VSV) recombinant expressing the SARS-
CoV S protein provides long-term protection of immunizedmice from SARS-CoV infection (Kapadia, S.U., Rose,
J. K., Lamirande, E., Vogel, L., Subbarao, K., Roberts, A., 2005. Long-term protection from SARS coronavirus
infection conferred by a single immunizationwith an attenuated VSV-based vaccine. Virology 340(2),174–82.).
Because it is difﬁcult to obtain regulatory approval of vaccine based on live viruses, we constructed a
replication-defective single-cycle VSV vector in which we replaced the VSV glycoprotein (G) gene with the
SARS-CoV S gene. The virus was only able to infect cells when pseudotyped with the VSV G protein. We
measured the effectiveness of immunization with the single-cycle vaccine in mice. We found that the vaccine
given intramuscularly induced a neutralizing antibody response to SARS-CoV that was approximately ten-fold
greater than that required for the protection from SARS-CoV infection, and signiﬁcantly greater than that
generated by the replication-competent vector expressing SARS-CoV S protein given by the same route. Our
results, alongwith earlier studies showing potent induction of T-cell responses by single-cycle vectors, indicate
that these vectors are excellent alternatives to live-attenuated VSV.




SARS (severe acute respiratory syndrome) emerged in the fall of
2002 in China but soon caught the world's attention as it quickly
spread to 28 countries. By the end of 2003 the World Health Or-
ganization reported over 8000 probable cases of SARS, a ﬁfth of which
occurred in health care workers. The overall fatality rate was 9.6%, but
in people over the age of 60, the rate exceeded 50%. (http://www.who.
int/csr/sars/en/WHOconsensus.pdf; Peiris et al., 2004)
The etiological agent was quickly identiﬁed as a coronavirus (CoV)
(Drosten et al., 2003; Ksiazek et al., 2003), and the 30 kb genome
sequence revealed a common coronavirus genome organization
(Marra et al., 2003; Rota et al., 2003). Six major open reading frames
were identiﬁed. Of those, four encoded the major structural proteins:
spike (S), membrane (M), nucleocapsid (N) and envelope (E). M, N and
E are involved in viral assembly and budding. S, themajor glycoprotein,
binds the cellular receptor, ACE 2 (Li et al., 2003), andmediates entry by
a class I viral fusion mechanism (Bosch et al., 2003).
There have been no reported cases of SARS since 2004; however
sources of the SARS-CoV still exist. Animal carriers of the virus in-
cluding Himalayan palm civets, raccoon dogs and bats have been iden-
tiﬁed (Guan et al., 2003; Lau et al., 2005; Li et al., 2005). Several cases ofy, Yale University School of
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lsevier Inc.laboratory-acquired SARS have also been reported. Because SARS-CoV
has not been eradicated, there is still a potential for human infections.
A SARS vaccine may be important in controlling future outbreaks.
Several experimental vaccines have been constructed and tested.
These include DNA vaccines, protein subunit vaccines, inactivated
SARS-CoV vaccine and recombinant viral vaccines (Gillim-Ross and
Subbarao, 2006). The SARS-CoV S glycoprotein has been used as the
antigen in the development of most of these SARS vaccines because it
is the target of virus neutralizing antibody.We previously reported the
development of an experimental VSV-based SARS vaccine. VSV (vesi-
cular stomatitis virus) is a negative strand RNA virus that belongs to
virus family Rhabdoviridae (Kapadia et al., 2005). Attenuated vectors
derived from VSV have been used extensively as experimental vaccine
candidates (Daddario-DiCaprio et al., 2006a,b; Egan et al., 2004;
Geisbert et al., 2005; Jones et al., 2005; Kahn et al., 2001; Natuk et al.,
2006; Palin et al., 2007; Ramsburg et al., 2004; Reuter et al., 2002;
Roberts et al., 1999,1998, 2004; Rose et al., 2001; Schlereth et al., 2003,
2000). They induce strong antibody and cellular immune responses,
and with the exception of some rural populations in Central and South
America, there is negligible seropositivity to VSV in the human pop-
ulation (Reif et al., 1987)making them attractive candidates for human
vaccination. For populations with pre-existing immunity to VSV, non-
endemic VSV serotype vectors can be used. VSV also grows to high
titers in cell lines approved for vaccine production.
In our initial study (Kapadia et al., 2005) we showed that a VSV
recombinant expressing the SARS-CoV S protein was capable of
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thermore, the immunized mice were protected from a SARS-CoV
challenge.We also showed that a humoral responsewas sufﬁcient for
protection. In the current study we generated and tested the
effectiveness of a VSV recombinant that is capable of undergoing
only one round of infection because it lacks the gene encoding the
VSV glycoprotein (G). Use of such a replication-deﬁcient vector
would overcome the complex regulatory issues related to approval of
live-virus vectors for use in humans. However, production of such
vectors would require a qualiﬁcation of a cell-line that expresses VSV
G or some plasmid DNA based complementation. Furthermore, a
single-cycle viral vaccine would alleviate concerns over potential
risks related to the use of live viral vectors in individuals with
weakened immune systems. In order to evaluate this vector as a SARS
vaccine candidate, we also developed a SARS-CoV neutralizationFig. 1. SARS-CoV S expressed by a single-cycle VSV recombinant. (A) The VSV G gene is repla
sequences are shown in the (+) anti-genomic sense. (B) The VSVΔG-EGFP1 lacks the VSV
sequences are shown in the (+) anti-genomic sense. (C) BHK-21 cells were infected with ei
immunoﬂuorescence. The ﬂuorescence images are shown on the left, and differential interfe
BHK-21 cells infected with wt VSV (lanes 1 and 2), VSV-S (lanes 3 and 4) or VSVΔG-S (lane
remove N-linked glycans from proteins (lanes 2, 4, and 6).assay using a pseudotyped VSV recombinant expressing a green
ﬂuorescent protein.
Results
Construction and characterization of a single-cycle VSV encoding the
SARS-CoV S protein
In order to recover a single-cycle VSV recombinant encoding the
S protein of SARS-CoV, the VSV glycoprotein (G) gene in a plasmid
expressing the VSV anti-genome was replaced with a gene encoding
SARS-CoV S (Fig. 1A). The resulting plasmid, pVSVΔG–SARS S, was used
to recover avirus, VSVΔG-S onBHK-21 cells expressingVSVG. BecauseG
is required for virus entry, VSV recombinants lacking theG genemust be
complemented with G in order to produce infectious particles. Virusesced by the SARS-CoV S gene in the VSV genome to yield the VSVΔG-S genome. The RNA
G gene and has an EGFP gene inserted into the ﬁrst position of the genome. The RNA
ther VSVΔG-S or wt VSV. Cells were ﬁxed, and SARS-CoV S was visualized by indirect
rence contrast (DIC) images are shown on the right. (D) Lysates of metabolically labeled
s 5 and 6) were analyzed by SDS-PAGE. The lysates were also treated with PNGase F to
Fig. 2. VSV G is needed to induce a SARS-CoV neutralizing response. Mice were
immunized i.m. with VSVΔG-S either G-complemented or (G) or non-complemented
with any viral glycoproteins (NC). Each virus was administered live or UV-inactivated
(UV). Serum SARS-CoV neutralizing antibody titers onemonth post-immunizationwere
determined in each group and used as a read out for replication in vivo. Error bars
indicate standard error of the mean. (N=5).
Fig. 3. VSV neutralizing antibody response. The VSV neutralizing antibodies titers of
samples collected at 5 weeks post-immunization are shown. The mean reciprocal di-
lution giving 100% neutralization is shown for each group. Error bars indicate standard
error of the mean.
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propagate further in the absence of a complementing G protein. When
VSVΔG-S was used to infect BHK-21 cells, we observed only single
infected cells and no virus spread, consistent with the absence of an
encoded VSV G protein.
To determine if the S protein was expressed by this recombinant,
we examined cells using indirect immunoﬂuorescence microscopy.
BHK-21 cells were infected with VSVΔG-S or wild type (wt) VSV, ﬁxed,
and then incubated with serum from a SARS-CoV-infected mouse. A
secondary, Alexa Fluor 488-conjugated anti-mouse antibodywas used
for visualization by confocal microscopy (Fig. 1C). We found that the
SARS-CoV S protein was expressed on the cell surface as indicated by
the strong surface ﬂuorescence signal visible in cells infected with
VSVΔG-S but not on control cells infected with wt VSV.
To evaluate viral protein expression further, we infected BHK-21
cells with wt VSV, VSV-S (Kapadia et al., 2005) or VSVΔG-S and
metabolically labeled cells with [35S]-methionine. Lysates of radi-
olabeled cells were analyzed by SDS-PAGE. Because VSV infection
shuts off host protein synthesis, the ﬁve VSV proteins L, G, N, P and M
are readily seenwithout immunoprecipitation (Fig. 1D, lane 1). VSV-S-
infected cells expressed the SARS-CoV S protein in addition to the ﬁve
VSV proteins (Fig. 1D, lane 3). VSVΔG-S-infected cells expressed S and
all of the VSV proteins except G (Fig. 1D, lane 5). Because S is a highly
glycosylated protein, we also treated the lysates with PNGase F to
remove glycans in order to further characterize S. After digestion, S
migrated faster on the gel (Fig. 1D, lanes 4 and 6), a change consistent
with removal of the predicted 17 glycans (Kapadia et al., 2005).
VSVΔG-S is a single-cycle vector in tissue culture and in mice
Because a low level of S protein of SARS-CoV is incorporated into
VSV particles (data not shown), it is possible that the S protein might
mediate infection in the absence of G. To determine if this S protein
could mediate infection of VSVΔG-S, we infected Vero E6 cells [cells
that express the SARS-CoV receptor, ACE2 (Ksiazek et al., 2003; Li
et al., 2003)] with G-pseudotyped VSVΔG-S. Using an immunoﬂuor-
escence microscopy assay for observing VSV N protein expression, we
saw single infected cells after 6 h but observed no infected cells after
24 h despite a near conﬂuent monolayer of live Vero E6 cells. This
result indicates that VSVΔG-S is not capable of a second round of
infection. Additionally, we passaged VSVΔG-S through BHK-21 cells to
yield progeny lacking VSVG and attempted to infect Vero E6 cells with
this virus stock. Even though we could detect S protein in these non-
complemented virions by Western blot, we did not observe any
infection of Vero E6 cells with these particles. These results indicated
that the S protein present on the virion was not capable of mediating
VSV entry in tissue culture. This is consistent with reported resultsshowing that the full-length S protein, as is encoded in VSVΔG-S, is
not capable of mediating infection of pseudotyped VSV (Fukushi et al.,
2005).
To determine if VSVΔG-S is able to replicate in vivowithout VSV G,
we inoculated mice intramuscularly (i.m.) with non-complemented
VSVΔG-S. If there were any infection by this virus, we anticipated that
there might be detectable immune responses to the S protein. We
measured SARS-CoV neutralizing antibody response as a measure of
replication. To control for possible immune responses to S protein on
the surface of particles in the inoculum, we also administered UV-
inactivated, non-complemented VSVΔG-S. As additional controls we
immunized two groups of mice with either G-complemented VSVΔG-
S or UV-inactivated, G-complemented VSVΔG-S. A dose of 5×105 pfu
(plaque forming units) of the G-complemented VSVΔG-S was used. An
equivalent particle dose of the non-complemented virus was assessed
from the amount of N protein in the virus preparation as determined
by Western blot.
One month after inoculation, serum was collected from each
animal and the SARS-CoV neutralization titers were determined. Only
the G-complemented VSVΔG-S-inoculated animals generated any
measurable neutralizing titers to SARS-CoV (Fig. 2). They averaged
1:128. The animals in the remaining groups including those ino-
culated with non-complemented VSVΔG-S made no measurable
neutralizing antibody response (even at an antibody dilution of 1:5)
indicating that signiﬁcant replication was not occurring. UV-inacti-
vated G-complemented VSVΔG-S did not induce a neutralizing
antibody response, indicating that one round of replication is essential
for a response.
We also assessed the immune responses to the VSV vector in these
animals. We used the serum from each animal to stain VSV-infected
cells and observed VSV N expression by immunoﬂuorescence mic-
roscopy. All animals immunized with live G-complemented VSVΔG-S
had an antibody response to N, while animals inoculated with non-
complemented VSVΔG-S had no detectable response to VSV. This
further supports the idea that VSVΔG-S is not infectious in animals
without VSV G.
Immune responses to VSVΔG-S
In order to test the potential of our single-cycle VSV recombinant
as a SARS vaccine, we conducted a study including ﬁve groups of mice.
The ﬁrst group included three control mice that received wt VSV
intranasally (i.n.). The second group of three mice was inoculated with
wt VSV i.m. The third group of six mice was immunized with VSV-S
administered i.n., while the fourth group of sixmice received VSV-S i.m.
The last group of ﬁve mice was vaccinated with VSVΔG-S i.m. A single
vaccine dose of 5×105 pfuwas administered. Serumwas collected from
all mice at 5, 9 and 13 weeks post-immunization.
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measured VSV neutralizing antibody titers in the serum of individual
mice at ﬁveweeks post-infection (Fig. 3). VSV G protein is the target of
VSV neutralizing antibodies (Kelley et al., 1972). All mice made mea-
surable neutralizing antibody titers to VSV consistent with successful
infection. Wt VSV administered i.n. produced the highest VSV
neutralizing titers (mean titer of 1:8533) consistent with previous
results (Kapadia et al., 2005).Wt VSV given i.m. and VSV-S given either
i.m. or i.n. producedmean VSV neutralizing titers between 1:2560 and
1:3760. The VSVΔG-S group produced a lower VSV neutralizing titer
(mean of 1:1408) consistent with the fact that this virus does not
encode a VSV G protein but does carry G protein on the particles
generated by complementationwith VSVG. These results indicate that
all mice had been effectively inoculated.
Development of a novel assay for SARS-CoV neutralizing antibody
Because a humoral response to the SARS-CoV S protein is sufﬁcient
for protection against SARS-CoV infection, we wanted to determine
the SARS-CoV neutralizing antibody titers in the serum of mice in this
study. In a previous study, we had used direct neutralization of SARS-
CoV to determine SARS-CoV neutralizing titers. In order to circumvent
the level of bio-containment required for this assay, we developed and
validated an assay using a VSVΔG virus expressing EGFP and com-
plemented with SARS-CoV S protein, the target of SARS-CoV neu-
tralizing antibodies.
We ﬁrst generated a VSV recombinant, VSVΔG–EGFP1. The genome
of this virus (Fig. 1B) has four VSV genes, N, P, L and M, and an EGFP
gene in the ﬁrst position of the VSV genome to promotemaximal EGFP
expression. Next we inserted the gene for a tagged SARS-CoV S protein
with its cytoplasmic tail replaced with an HA epitope tag (SΔtail-HA)
into a mammalian expression vector, pCAGGS (Niwa et al., 1991). The
deletion of the tail is required for infection in the context of pseu-
dotyped viruses (Fukushi et al., 2005; Giroglou et al., 2004; Moore
et al., 2004). This plasmid was transfected into BHK-21 cells. When the
transfected cells were expressing SΔtail-HA protein, they were in-Fig. 4. Speciﬁc neutralization of VSVΔG-EGFP1/SΔtail-HA by anti-S antibody. VSVΔG-EGFP1
from mice immunized with wt VSV, VSV-S or SARS-CoV as indicated. The pseudotypes wer
ﬂuorescence images and differential interference contrast (DIC) images are shown for eachfected with VSVΔG–EGFP1 complemented with VSV G. The virus was
adsorbed for 1 h, and the cells were thenwashed three times with PBS
in order to remove the input particles. Themediawas replaced and the
infectionwas allowed to continue for 24 h. The resulting pseudotyped
virus, VSVΔG–EGFP1/SΔtail-HA, was present in the media collected
from these cells.
We next determined if the pseudotyped VSVΔG–EGFP1/SΔtail-HA
could be used to assay for SARS-CoV neutralizing antibodies. We
incubated the pseudotyped virus with antiserum from mice inocu-
lated with either wt VSV (which have neutralizing antibody directed
to VSV G only), VSV-S (which have neutralizing antibody to VSV and
SARS-CoV), or SARS-CoV (which have antibody to SARS-CoV only) at a
dilution of 1:50 to ascertain which antibodies were capable of neu-
tralizing the pseudotyped virus. We used VSVΔG–EGFP1 pseudotyped
with VSV G as a control to measure neutralizing antibodies that react
with VSV G. Following a one-hour incubation at 37 °C, the virus-serum
mixtures were then transferred to a monolayer of Vero E6 cells, which
express the SARS-CoV receptor, ACE 2 (Ksiazek et al., 2003; Li et al.,
2003). The cells were incubated at 37 °C for 18 h and then ﬁxed with
3% paraformaldehyde. We determined infection by observing EGFP
expression using ﬂuorescence microscopy.
Infection of Vero E6 cells by the VSVΔG-EGFP1/SΔtail-HA pseudo-
typeswas not neutralized by antibodies to VSV, but was neutralized by
antibodies to VSV-S (which contains antibodies to VSV and S) or SARS-
CoV (which contains antibodies to S). In contrast VSVΔG-EGFP1/Gwas
not neutralized by antibody to SARS-CoV, but was neutralized by
antiserum to VSV or VSV-S (Fig. 4). These results show that neu-
tralization of the S-pseudotyped virus was speciﬁc for antibody to
SARS-CoV S.
The VSVΔG–EGFP1/SΔtail-HA pseudotype assay is as sensitive as the
direct SARS-CoV neutralization assay
We next compared the sensitivity of our neutralization assay with
the standard assay using serum standards assayed previously with
the direct SARS-CoV neutralization assay. We used sera from micepseudotyped with either SΔtail-HA or VSV G proteins were incubated with antiserum
e then transferred to Vero E6 cells. Infection was determined by EGFP expression. Both
ﬁeld.
Fig. 5. SARS-CoV neutralizing antibody responses to each vector. The SARS-CoV neutralizing antibody titers of serum of individual mice at 5 weeks (A), 9 weeks (B) and 13 weeks (C)
post-immunization are given. The reciprocal dilutions giving 100% neutralization for each group are shown. The mean reciprocal dilutions giving 100% neutralization for each group
over time are summarized (D). Mice immunized with wt VSV, either i.m or i.n., had no detectable SARS-CoV neutralizing antibodies. Error bars indicate standard error of the mean.
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SARS vaccine study (Kapadia et al., 2005). SARS-CoV neutralizing
antibody titers of these sera were determined by incubating VSVΔG-
EGFP/SΔtail-HA virus with serial dilutions of these sera, and the virus-
serum mixtures were transferred to a monolayer of Vero E6 cells.
Infection was determined by observing EGFP expression by ﬂuores-
cence microscopy 18 h after infection. The titer was deﬁned as the
highest dilution that completely neutralized VSVΔG-EGFP1/SΔtail-
HA. There was no detectable neutralizing activity in serum from mice
vaccinated with wt VSV. The titers in serum samples from VSV-S- and
SARS-CoV-inoculated mice were determined to be 1:40 and 1:20
respectively in pseudotype assay. These titers of these sera were 1:32
and 1:12 in the direct assay. Furthermore these sera were from mice
that were able to control SARS-CoV infection upon challenge. Since an
antibody response is sufﬁcient for protecting against SARS-CoV (Bisht
et al., 2004; Kapadia et al., 2005; Yang et al., 2004), a titer neutralizing
titer of as low as 1:20 is indicative of protection.
VSVΔG-S induces a response indicative of protection
We then used this neutralization assay tomeasure the neutralizing
antibody titers in the serum of the mice in our current study (Fig. 5).
No SARS-CoV-neutralizing antibodies were detected in animals that
were infected by wt VSV. There was little variability between in-
dividual mice within a group at the three time points measured
(Fig. 5A, B and C). Notably animals made neutralizing antibodies titers
that were considerably greater than 1:20, a titer we determined
previously to be protective against SARS-CoV challenge. Animals
infected by VSV-S i.n. produced the most robust responsewith a mean
titer of 1:906 ﬁve weeks post-vaccination (Fig. 5D). This level dropped
by to 1:426 by nine weeks post-vaccination. The group immunized
with VSVΔG-S also made a strong antibody response with average
titers approximately 1:200 at all time points tested. This response was
about two-fold greater than that seen in the group immunized i.m.with the replication-competent VSV-S. This differencewas statistically
signiﬁcant at 13 weeks post-immunization (p=0.0087, Mann–Whit-
ney test). A similar trend was previously reported with a single-cycle
VSV vector expressing the HIV Env protein. It generally generated a
better T-cell response to HIV Env than the replication-competent VSV
vector expressing HIV Env when administered i.m., though the
difference was not statistically signiﬁcant (Publicover et al., 2005).
Discussion
Regulatory approval for the use of replication-competent VSV-
based vaccine vectors in humans has been slow because of concerns
about potential pathogenesis. We therefore have developed single-
cycle VSV-based vectors lacking the VSV G gene that can infect cells,
but cannot produce infectious particles (Schnell et al., 1997). We
report here that such a replication-defective vector expressing the
SARS-CoV S protein is highly effective at generating SARS-CoV neu-
tralizing antibody in animals when given i.m. and is even better than a
replication-competent VSV vector expressing SARS-CoV S given by the
same route.
We were concerned that the single-cycle VSVΔG-S vaccine vector
described here might be able to mediate multiple rounds of infection
because some S protein is incorporated into virions. However, we did
not detect any infection bynon-G-complementedVSVΔG-S particles in
cells expressing the SARS-CoV receptor. Furthermore, when we
inoculated mice with these non-complemented pseudotyped parti-
cles, we saw no immune responses to S or to VSV N indicating that no
signiﬁcant infection occurred. Others have also reported that full-
length SARS-CoV Swas not able tomediate entry of VSV and found that
a deletion in the carboxy-terminal tail was required for S-mediated
entry (Fukushi et al., 2005). The tail of S was also inhibitory in me-
diating entry of retroviruses (Giroglou et al., 2004; Moore et al., 2004).
It is likely that the S tail sequence negatively regulates the membrane
fusion activity of the S protein, and that in SARS-CoV virions, other
170 S.U. Kapadia et al. / Virology 376 (2008) 165–172proteins function to activate the S protein membrane fusion activity.
Consistent with these earlier reports, we found that the full-length
S protein would not pseudotype VSVΔG-EGFP to generate infectious
virions, while S protein with its cytoplasmic tail deleted and replaced
with an HA tag pseudotyped effectively. Taken together, all evidence
indicates that VSVΔG-S is a single-cycle vector.
The strength of the immune response to proteins expressed by
replication-competent VSV vectors given i.n. correlates positively
with their ability to replicate and spread systemically (Publicover
et al.,2005; Simon et al., 2007). Single-cycle vectors, which do not
spread systemically (Simon et al., 2007), are relatively poor vectors
when given i.n., yet generate strong immune responseswhengiven i.m.
(Publicover et al., 2005). In the studies reported here we therefore
tested the single-cycle VSVΔG-S vector only by the intramuscular
route. We found that one dose of the vector was able to generate high
levels of SARS-CoV neutralizing antibody titers of about 1:200. These
neutralizing titers were at least ten-fold greater than what was re-
quired for complete protection against SARS-CoV replication inmice in
our previous study (Kapadia et al., 2005), and two-fold greater than
those induced by the replication-competent VSV-S given i.m.. Because
antibody responses are sufﬁcient for controlling SARS-CoV infection
(Kapadia et al., 2005; Yang et al., 2004), these titers are predictive of
protection in the mouse model.
Although the SARS-CoV neutralizing antibody titers obtained from
mice immunized i.n. with replication-competent VSV-S were higher
(average∼1:600) than the titers obtained fromanimals immunized i.m.,
we also know that the replication-competent vectors spread systemi-
cally after vaccination by this route (Simon et al., 2007). The virus
replicates in the lungs, causes a viremia, and spreads tomultiple organs.
Such widespread dissemination of the vector could also raise safety
concerns.
How canwe explain the greater potency of the single-cycle vectors
relative to replication-competent vectors given i.m.? First, we have
evidence that replication-competent and single-cycle vectors are both
effectively single-cycle vectors when given i.m. (Ian Simon, unpub-
lished results). Second, the single-cycle vector may be more effective
because of the greater expression of S protein in the absence of the
upstream G protein gene. Because of transcriptional attenuation
(Iverson and Rose, 1981), the removal of the G gene leads to greater
transcription and expression of the SARS-CoV S gene. In order to
evaluate this possibility, we quantiﬁed the expression of S (treated
with PNGase F) by VSV-S and VSVΔG-S relative to N/P expression in
the gel shown in Fig. 1D. We found that VSVΔG-S expresses appro-
ximately 47% more S protein than VSV-S. Lastly, it is also possible that
expression of G protein from the replication-competent vector
competes with the S protein for the antibody response.
The results reported here, along with earlier studies showing
potent induction of cellular immune responses by single-cycle vectors
(Publicover et al., 2005), indicate that these single-cycle vectors are
excellent alternatives to live-attenuated VSV vaccine vectors and that
they warrant further development.
Material and methods
Plasmids
To construct pVSVΔG-SARS S, the SARS-CoV S gene was ampliﬁed
from pVSV-SARS S (Kapadia et al., 2005) by PCR using the following
primers: 5′-GATCGATCACGCGTAACATGTTTATTTTCTTATTATTTC-3′
and 5′-CGATCCCCCCGGGCTAGCTTATGTGTAATGTAATTTGACACCC-3′.
The PCR product was digested with MluI and NheI (sites underlined)
and ligated to the puriﬁed 12,704 bp fragment resulting from the
digestion of pVSVXN2 (Schnell et al., 1996) with the same enzymes.
The plasmid pVSVΔG-EGFP1 expressing EGFP from the ﬁrst
position in the genome was generated by digesting pVSV1XN-EGFP
(Ramsburg et al., 2005) with HpaI and XbaI. The ∼12-kb vectorfragment was puriﬁed and ligated to the ∼1.4 kb fragment resulting
from the digestion of pVSVΔG (Roberts et al., 1999) with the same
enzymes. The resulting plasmid was designated pVSVΔG-EGFP1.
pCAAGS-SARS SΔtail-HA was made by PCR ampliﬁcation of the
SARS-CoV S gene with primers that replaced the region encoding the
last 28 residues of the carboxy-terminal tail with a sequence encoding
the HA epitope tag. The following primers were used: 5′-GATC-
GATCCTCGAGAACATGTTTATTTTCTTAATTATTTC-3′ and 5′-CGATC-
CCCCCGGGCTAGCTTAGGCGTAATCTGGGACGTCGTATGGGTACTTGAGG-
CAACTGCAACAACTAGTC-3′. The sequence encoding the HA tag is
shown in bold. The resulting PCR product was digested with XhoI and
NheI (sites underlined) and ligated into pCAAGS (Niwa et al., 1991)
also digested with the same enzymes. Construction of pCAAGS-G was
previously described (Okuma et al., 2001).
Recombinant VSV recovery and preparation
Viruses were recovered from plasmids pVSVΔG–SARS S and
pVSVΔG–EGFP1 by previously described methods (Schnell et al., 1997).
The recovered viral supernatants were then transferred onto BHK-21
cells that had been transfected (described below) with pCAAGS-G
(Okumaet al., 2001). The supernatants containing VSVΔG-S andVSVΔG-
EGFP1 complemented with G were collected after 36 h. The viruses
were titered on BHK-G cells (Schnell et al.,1997) using a standard plaque
assay.
To obtain VSVΔG-EGFP1 pseudotyped with the SΔtail-HA protein,
we transfected BHK-21 cell with pCAAGS-SARS SΔtail-HA (described
below). Transfected cells were infected with recovered VSVΔG-EGFP1
complemented with VSV G. One hour after infection, the input virus
was removed and the cells were washed 3 times with phosphate
buffered saline (PBS). DMEM containing 5% FBS was added to the cells.
The media containing VSVΔG-EGFP1 complemented with SΔtail-HA
was collected after 36 h. The virus was titered on Vero E6 cells by
assessing the number of cells expressing EGFP.
VSV-SARS S (VSV-S) (Kapadia et al., 2005) and wt VSV (Lawson
et al., 1995) recovery were previously described.
Non-complemented VSVΔG-S was obtained by infecting BHK-21
cells with VSVΔG-S at an MOI of 5 for 1 h. The cells were thenwashed
5 times with PBS to remove any input virus. DMEM with 5% FBS was
added to the cells and incubated overnight. The media was collected
and subjected to ultracentrifugation for 1 h at 100,000 ×g in order to
concentrate virus.
Transfections
Nine micrograms of DNA was diluted in 0.6 ml of OptiMEM
(Invitrogen, Carlsbad, CA), and 30 μl of Lipofectamine Reagent
(Invitrogen, Carlsbad, CA) was also diluted in 0.6 ml of OptiMEM.
The DNA and Lipofectamine mixtures were combined and incubated
for 30 min at room temperature. BHK-21 cells (2×106 cells plated 18 h
earlier) werewashedwith PBS, and 4.8ml of OptiMEMwas added. The
DNA/Lipofectamine was added to the cells and incubated at 37 °C for
5 h. Then 6 ml of Dulbecco's modiﬁed Eagle's medium (DMEM)
containing 20% fetal bovine serum (FBS) was added and left overnight
at 37 °C. The next morning the media was replaced with DMEM
containing 5% FBS. The transfection was allowed to continue for 48 h
after the addition of the DNA/Lipofectamine mixture.
Metabolic labeling
BHK-21 cells were infected with wt VSV, VSV-S or VSVΔG-S at a
multiplicity of infection (MOI) of 20. After 5 h the cells were washed
twice with methionine-free DMEM and incubated with 100 μCi of
[35S]-methionine in 1 ml of methionine-free DMEM for 30 min at
37 °C. The cells were thenwashed twice with PBS and solubilized with
a detergent solution (1% Nonidet P-40, 0.4% deoxycholate, 50 mM
171S.U. Kapadia et al. / Virology 376 (2008) 165–172Tris–HCl [pH 8], 62.5 mM EDTA). Lysates were analyzed by SDS-PAGE.
The protein samples were treated with Peptide N-Glycosidase
(PNGase) F (New England Biolabs, Beverly, MA) according to manu-
facturer's instructions.
Fluorescence microscopy
For indirect immunoﬂuorescence microscopy, BHK-21 cells plated
on glass coverslips were infectedwith either wt VSV or VSVΔG-S. After
6 h the cells were washed twice with PBS and ﬁxed with 3% para-
formaldehyde. The cells were then washed twice with PBS containing
10 mM glycine and incubated with serum from a SARS-CoV infected
mouse at a dilution of 1:200. The coverslips were washed twice with
PBS-glycine and incubated with Alexa Fluor 488 goat anti-mouse IgG
(Molecular Probes, Eugene, OR) diluted 1:500. The cells were washed
twice with PBS-glycine and mounted on slides. Cells were imaged
using a Biorad μ Radiance confocal scanning system on a Nikon Elipse
TE300 microscope with a 60× planapochromat objective.
Fluorescence microscopy to visualize EGFP was performed with a
NikonMicrophot FXmicroscope equippedwith a 40× planapochromat
objective, epiﬂuorescence, and a Spot digital camera.
Vaccination protocol
Ten-week-old BALB/c mice (Charles River Laboratories) were used
in this study. Single intranasal inoculations of 5×105 plaque forming
units (pfu) of wt VSV and VSV-S were administered in a volume of
25 μl to animals lightly anesthetized with 20% Isoﬂurane (Baxter,
Deerﬁeld, IL) diluted in propylene glycol (v/v). Single intramuscular
inoculations of 5×105 pfu of wt VSV, VSV-S and VSVΔG-S were
administered in a volume of 50 μl in the hind leg muscle.
Virus neutralization assays
The VSV neutralization titers are deﬁned as the highest dilution of
serum that can completely neutralize infectivity of 100 pfu of VSV on
BHK-21 cells. This assay was described previously (Rose et al., 2001).
In order to measure SARS-CoV neutralizing antibodies in serum,
VSVΔG-EGFP1/ SΔtail-HA was ﬁrst incubated with two monoclonal
antibodies, I1 and I14 (Lefrancois and Lyles, 1982), at a dilution of
1:1000 per antibody for 1 h at 37 °C to neutralize potential infection
due to any residual VSV G that may have been incorporated into the
particles pseudotyped with SΔtail-HA protein. Serum samples were
serially diluted with DMEM containing 5% FBS. Approximately 75
infectious pseudotyped particles were added to each serum dilution in
a ﬁnal volume of 30 μl. The mixture was incubated for an hour at 37 °C.
25 μl of each dilution was transferred to a monolayer of Vero E6 cells
grown in a 96-well plate. After 1 h at 37 °C, 50 μl of DMEMwith 5% FBS
was added to each well and the cells were incubated for 16 to 20 h at
37 °C. Infection was determined by visualizing EGFP expression using
an Olympus CK40 microscope equipped for epiﬂuorescence. Each
dilution was measured in duplicate. The titer was determined to be
the highest dilution at which both duplicates showed no infection.
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